Table 6.
Competing risks analysis for cancer-specific death
| SHR* (95% CI*) | P | |
|---|---|---|
| N stage | ||
| N0 | Reference | |
| N1/N2 | 2.96 (2.30–3.82) | < 0.001 |
| Tumor size (cm) | ||
| < 1 | Reference | |
| 1–1.9 | 1.09 (0.75–1.59) | 0.670 |
| 2–2.9 | 1.17 (0.78–1.74) | 0.461 |
| 3+ | 1.50 (1.03–2.19) | 0.026 |
| Not stated | 0.93 (0.63–1.37) | 0.720 |
| Histology | ||
| Adenocarcinoma | Reference | |
| Mucinous carcinoma | 1.46 (0.91–2.36) | 0.130 |
| CEA* | ||
| Positive | Reference | |
| Negative | 0.45 (0.31–0.64) | < 0.001 |
| Borderline/unknown | 0.48 (0.34–0.68) | < 0.001 |
| Grade | ||
| Well-differentiated | Reference | |
| Moderately differentiated | 1.08 (0.80–1.45) | 0.730 |
| Poorly differentiated | 1.60 (1.06–2.42) | 0.031 |
| Undifferentiated | 2.91 (1.19–7.15) | 0.022 |
| Unknown | 0.90 (0.55–1.49) | 0.601 |
| Year | ||
| 2004–2006 | Reference | |
| 2007–2009 | 0.84 (0.65–1.10) | 0.180 |
| 2010–2012 | 0.60 (0.44–0.82) | 0.001 |
| Age (years) | ||
| Up to 49 | Reference | |
| 50–64 | 1.06 (0.65–1.72) | 0.841 |
| 65–79 | 1.61 (1.00–2.58) | 0.048 |
| 80+ | 3.01 (1.82–4.98) | <0.001 |
| Race | ||
| Black | Reference | |
| White | 0.57 (0.43–0.76) | < 0.001 |
| Others | 0.48 (0.28–0.81) | 0.007 |
| Marital status | ||
| Married | Reference | |
| Single/widowed | 1.45 (1.13–1.87) | 0.003 |
| Other/unknown | 0.96 (0.67–1.38) | 0.860 |
| Primary site | ||
| Cecum | Reference | |
| Ascending colon | 1.21 (0.89–1.65) | 0.230 |
| Hepatic flexure | 0.96 (0.56–1.65) | 0.881 |
| Transverse colon | 1.05 (0.66–1.69) | 0.832 |
| Splenic flexure | 0.20 (0.03–1.39) | 0.102 |
| Descending colon | 1.09 (0.61–1.92) | 0.781 |
| Sigmoid colon | 1.12 (0.81–1.55) | 0.490 |
*SHR subdistribution hazard ratio, 95% CI 95% confidence intervals, CEA carcinoembryonic antigen